AstraZeneca Presents Results of Imfinzi (durvalumab) + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV NSCLC at WCLC 2021

September 13, 2021 Auto Bot AstraZeneca, Clinical Trials, durvalumab, Imfinzi, Non-Small Cell Lung Cancer, P-III 0

Shots:

  • The P-III POSEIDON trial evaluates Imfinzi (1500mg, q3w, FD, for 4 cycles) + Pt-based CT or Imfinzi + Tremelimumab + CT vs CT alone in 1013 patients with mNSCLC
  • The results showed an improvement in OS & PFS, 28% reduction in risk of cancer progressing or death with an m-PFS (6.2 vs 4.8mos.), 23% reduction in risk of death @16wks., m-OS (14.0 vs 11.7mos.), patients were alive @2yrs. (33% vs 22%). The safety profile was consistent with known profiles of therapies & no new safety signals were observed
  • Imfinzi is further being evaluated across all stages of lung cancer and in other tumor types. The combination therapy also tested for lung cancer, bladder cancer, and liver cancer

Click here to read full press release/ article | Ref: AstraZeneca | Image: New Europe

The post AstraZeneca Presents Results of Imfinzi (durvalumab) + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV NSCLC at WCLC 2021 first appeared on PharmaShots.